Titre : | Focus on cannabinoids and synthetic cannabinoids (2017) |
Auteurs : | R. LE BOISSELIER ; J. ALEXANDRE ; V. LELONG-BOULOUARD ; D. DEBRUYNE |
Type de document : | Article : Périodique |
Dans : | Clinical Pharmacology and Therapeutics (Vol.101, n°2, February 2017) |
Article en page(s) : | 220-229 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés DROGUES DE SYNTHESE ; CANNABINOIDES ; NEUROBIOLOGIE ; CHIMIE ; PHARMACOLOGIE ; RECEPTEUR ; USAGE RECREATIF ; EFFET RECHERCHE ; EFFET SECONDAIRE ; USAGE THERAPEUTIQUE |
Résumé : | The recent emergence of a multitude of synthetic cannabinoids (SCs) has generated a wealth of new information, suggesting the usefulness of state-of-the-art on lato sensu cannabinoids. By modulating a plurality of neurotransmission pathways, the endocannabinoid system is involved in many physiological processes that are increasingly explored. SCs desired and adverse effects are considered to be more intense than those observed with cannabis smoking, which is partly explained by the full agonist activity and higher affinity for cannabinoid receptors. Neurological and cardiovascular side effects observed after cannabinoid poisoning generally respond to conventional supportive care, but severe outcomes may occur in a minority of cases, mainly observed with SCs. The likelihood of severe abuse and addiction produced by SCs are of concern for the scientific community also interested in the potential therapeutic value of cannabinoids. |
Domaine : | Drogues illicites / Illicit drugs |
Sous-type de document : | Revue de la littérature / Literature review |
Refs biblio. : | 77 |
Affiliation : |
University Hospital Centre Cote de Nacre, Centre for Evaluation and Information on Pharmacodependance - Addictovigilance (CEIP-A), Caen, France |
Accueil